Silexion Therapeutics Ltd.
SLXNW · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $1 | $5 | $8 | $0 |
| + Debt | $4 | $0 | $0 | $0 |
| Enterprise Value | $3 | -$4 | -$8 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$16 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |
| Net Income | -$16 | -$5 | $1 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | 25.49 | 0.39 | 0.35 | -0.46 |
| % Growth | 6,435.9% | 11.4% | 176.1% | – |
| Operating Cash Flow | -$8 | -$5 | -$3 | -$1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$8 | -$5 | -$3 | -$1 |